

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal

Cabozantinib and vandetanib for treating unresectable locally advanced or metastatic medullary thyroid cancer [ID56]

Final matrix of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|--|--|
| <p><u>Companies</u></p> <ul style="list-style-type: none"> • Genzyme Therapeutics (vandetanib) • Ipsen (cabozantinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Butterfly Thyroid Cancer Trust • Cancer 52 • Cancer Black Care • Cancer Equality • Changing Faces • Get-A-Head • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Let's Face it • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Mouth Cancer Foundation • Muslim Council of Britain • National Association of Laryngectomee Clubs • Rarer Cancers Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Association of Endocrine and Thyroid Surgeons • British Association of Surgical | <p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Genzyme Therapeutics (vandetanib) • Ipsen (cabozantinib) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Oracle Cancer Trust • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales |

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| <p>Oncology</p> <ul style="list-style-type: none"> • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Thyroid Association • Cancer Research UK • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Hastings & Rother CCG • NHS West Hampshire CCG • Welsh Government | |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

MTA Definitions:

National Institute for Health and Care Excellence
 Matrix for the technology appraisal of cabozantinib and vandetanib for treating unresectable locally advanced or metastatic medullary thyroid cancer [ID56]
 Issue date: October 2016

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.